Related Experiment Video
Updated: May 7, 2026
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Extended adjuvant chemotherapy in endocrine non-responsive disease
Marco Colleoni1, Elisabetta Munzone
1Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
Breast (Edinburgh, Scotland)
|October 1, 2013
Summary
Longer adjuvant chemotherapy may benefit patients with endocrine-non-responsive breast cancer, particularly triple-negative types. Conventional chemotherapy (4-6 months) is adequate for low/no steroid hormone receptor expression tumors.
Area of Science:
- Oncology
- Breast Cancer Research
- Chemotherapy Efficacy
Background:
- Endocrine-non-responsive breast cancers exhibit rapid proliferation and high relapse risk.
- Triple-negative breast cancer lacks targets for endocrine or anti-HER2 therapies.
- Prolonged chemotherapy may be crucial for managing these aggressive tumor subtypes.
Purpose of the Study:
- To evaluate the optimal duration of adjuvant chemotherapy for breast cancer.
- To identify patient subpopulations that may benefit from extended chemotherapy regimens.
- To synthesize evidence from trials addressing chemotherapy duration in endocrine-non-responsive disease.
Main Methods:
- Review of several clinical trials addressing adjuvant chemotherapy duration in breast cancer.
- Analysis of studies comparing different chemotherapy durations and drug regimens.
- Consideration of trial limitations, including small sample sizes and confounding factors.
Main Results:
- Incremental chemotherapy strategies have shown greater efficacy in past studies, especially for endocrine-non-responsive disease.
- Many trials were too small to detect modest differences in biological subtypes.
- Confounding of drug choice and duration limited definitive conclusions in some studies.
Conclusions:
- Conventional-dose chemotherapy for 4-6 months is adequate for tumors with low or no steroid hormone receptor expression.
- Endocrine-non-responsive tumors are a heterogeneous group including basal-like and HER-enriched subtypes.
- International collaboration is needed to establish consensus on treating endocrine-non-responsive breast cancer.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...